Nuvectis Pharma, Inc. Common Stock (NVCT) Stock
Key stats
- Market cap
- $722.17M
- Price / Earnings ratio
- -14.4x
- EPS (TTM)
- -$1.89
- Volume
- Loading
- 52-week high
- $29.28
- 52-week low
- $5.77
Source: third-party data provider, as of November 13, 2026
Compare with NVCT
Recent news

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NVCT

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NVCT

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NVCT
Technical indicators
- RSI 14
- 56.42
- MACD 12/26/9
- 0.01
- EMA 9 of MACD
- -0.34
- MACD histogram
- 0.35
- SMA 50
- $20.76
- Price above SMA 50
- EMA 50
- $20.10
- Price above EMA 50
- SMA 200
- $15.06
- Price above SMA 200
- EMA 200
- $15.23
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NVCT

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NVCT

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NVCT

What Makes Nuvectis Pharma (NVCT) a New Buy Stock
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
NVCT

Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
NVCT

5 Healthcare Stocks to Buy for 2024
5 Healthcare Stocks to Buy for 2024
NVCT

3 Best Breakout Stocks Worth Buying for Superlative Returns
3 Best Breakout Stocks Worth Buying for Superlative Returns
NVCT
About Nuvectis Pharma, Inc. Common Stock
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1966 |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 1967 |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 1984 |
| Mr. Michael Carson CPA | Vice President of Finance | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.42
- MACD 12/26/9
- 0.01
- EMA 9 of MACD
- -0.34
- MACD histogram
- 0.35
- SMA 50
- $20.76
- Price above SMA 50
- EMA 50
- $20.10
- Price above EMA 50
- SMA 200
- $15.06
- Price above SMA 200
- EMA 200
- $15.23
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $39.00
- Average
- $39.00
- High
- $39.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +10.2 | +5.2 | -8.4 | -10.8 | +9.5 |



